selatogrel

Selatogrel is a potent, reversible, and selective small molecule antagonist of the P2Y12 receptor, developed for subcutaneous administration. It is designed to inhibit platelet aggregation by blocking the P2Y12 receptor on platelets, thereby preventing blood clots that can lead to acute cardiovascular events such as myocardial infarction (heart attack). Selatogrel acts rapidly after injection and its effects are reversible, distinguishing it from some other antiplatelet agents. The drug is being developed primarily for emergency treatment in patients with acute myocardial infarction and has shown rapid onset of action in clinical trials. Its development aims to address limitations of current oral and intravenous P2Y12 inhibitors by providing fast, reliable platelet inhibition suitable for self-administration or use in emergency settings[1][3][4][5][6][7].

Other names

selatogrelACT-246475ACT246475ACT 246475